Britain and America have agreed to a key bilateral deal that will ensure no import taxes on British drug exports entering the US market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has pledged to increase expenditure on drugs through the public health system. This commitment secures that tariffs on these vital goods will stay at zero for a timeframe of the next three years.
This agreement is in response to recent warnings to dramatically increase duties on patented drug imports, with figures floated as high as one hundred percent.
"This agreement between the United Kingdom bolsters the international landscape for innovative medicines and brings long-overdue balance to U.S.–U.K. pharmaceutical trade," a statement declared.
Economic Impact
Medicines are one of the UK's largest goods shipped to the United States, which is clearly the biggest market for major companies like GSK and AstraZeneca.
Statistics show that in the year prior to the third quarter, the UK shipped medicines totaling over eleven billion pounds to the US. This amount made up nearly one-fifth of all goods exports in that timeframe.
"This guarantee protects work, increases capital expenditure and sets the stage for the UK to emerge as a global hub for biotech and pharma," a minister commented.
Specific UK Commitments
The pact entails several notable pledges from the UK:
- Price Threshold Increase: The UK will increase the cost ceiling at which it deems new medicines to be too expensive by a quarter.
- Higher Drug Budget: There is a target to increase overall public funding on treatments from 0.3% of GDP to 0.6% over the following ten-year period.
- Refund Ceiling: The sum pharmaceutical firms must pay back to the NHS to control costs will be limited at 15%. Last year, refunds topped 20%.
Broader Context
The deal comes amid a protracted row between the drug companies and the UK government over drug pricing and NHS adoption.
This friction were heightened by assertions that US patients were paying a premium for the equivalent treatments than people in the other developed nations.
Recently, several large pharmaceutical investments in the UK have been paused or scrapped, while multi-billion-dollar funding commitments have been directed toward US facilities.
One official publicly accepted that the NHS needed to increase expenditure on treatments, noting that its expenditure on drugs had declined as a percentage of its overall budget over the last ten years.